The $1,000 Genome et plus d'un million d'autres livres sont disponibles pour le Kindle d'Amazon. En savoir plus


ou
Identifiez-vous pour activer la commande 1-Click.
Plus de choix
Vous l'avez déjà ? Vendez votre exemplaire ici
Désolé, cet article n'est pas disponible en
Image non disponible pour la
couleur :
Image non disponible

 
Commencez à lire The $1,000 Genome sur votre Kindle en moins d'une minute.

Vous n'avez pas encore de Kindle ? Achetez-le ici ou téléchargez une application de lecture gratuite.

The $1,000 Genome: The Revolution in DNA Sequencing and the New Era of Personalized Medicine [Livre audio, MP3 Audio, Version intégrale] [Anglais] [MP3 CD]

Kevin Davies , Johnny Heller
5.0 étoiles sur 5  Voir tous les commentaires (1 commentaire client)
Prix : EUR 20,70 Livraison à EUR 0,01 En savoir plus.
  Tous les prix incluent la TVA
o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o
Il ne reste plus que 1 exemplaire(s) en stock (d'autres exemplaires sont en cours d'acheminement).
Expédié et vendu par Amazon. Emballage cadeau disponible.

Formats

Prix Amazon Neuf à partir de Occasion à partir de
Format Kindle EUR 14,80  
Relié EUR 16,84  
MP3 CD, Livre audio, MP3 Audio, Version intégrale EUR 20,70  

Description de l'ouvrage

21 septembre 2010
In 2000, President Bill Clinton signaled the completion of the Human Genome Project at a cost in excess of $2 billion. A decade later, the price for any of us to order our own personal genome sequence—a comprehensive map of the 3 billion letters in our DNA—is rapidly and inevitably dropping to just $1,000. Dozens of men and women—scientists, entrepreneurs, celebrities, and patients—have already been sequenced, pioneers in a bold new era of personalized genomic medicine. The $1,000 genome has long been considered the tipping point that would open the floodgates to this revolution.

Do you have gene variants associated with Alzheimer’s or diabetes, heart disease or cancer? Which drugs should you consider taking for various diseases, and at what dosage? In the years to come, doctors will likely be able to tackle all of these questions—and many more—by using a computer in their offices to call up your unique genome sequence, which will become as much a part of your medical record as your blood pressure. Indeed, many experts are advocating that all newborns have a complete genome analysis done so that preventive measures and preemptive medicine can begin early in life.

How has this astonishing achievement been accomplished? And what will it mean for our lives? To research the story of this unfolding revolution, critically acclaimed science writer Kevin Davies has spent the past few years traveling to the leading centers and interviewing the entrepreneurs and pioneers in the race to achieve the $1,000 genome. He vividly brings to life the extraordinary drama of this grand scientific achievement, revealing the masterful ingenuity that has transformed the process of decoding DNA and delivering the information it possesses to the public at large.

Davies also profiles the future of genomic medicine and thoughtfully explores the many pressing issues raised by the tidal wave of personal genetic information. Will your privacy be protected? Will you be pressured, by insurance companies or by your employer, to get your genome sequenced? What psychological toll might there be to discovering you are at risk for certain diseases like Alzheimer’s? And will the government or the medical establishment come between you and your genome?

One thing that is not in question is that we are moving swiftly into the personalized medicine era, and The $1,000 Genome is an essential guide to this brave new future.
--Ce texte fait référence à l'édition Relié .

Offres spéciales et liens associés


Descriptions du produit

Revue de presse

``The great impact of a new technology – from cotton underwear to the jet to the computer – comes not when it is invented, but when it becomes cheap enough to be within the reach of everybody. Gene sequencing has now reached that point. With unrivalled knowledge of the people who made this possible, Kevin Davies eloquently explains how it came about, and hints at what will come next.’’ (Matt Ridley, author of The Rational Optimist) --Ce texte fait référence à l'édition Relié .

Biographie de l'auteur

Kevin Davies, Ph.D., is the author of The $1,000 Genome. His previous book Cracking the Genome was translated into 15 languages. He is currently Editor-in-Chief of Bio•IT World, a trade magazine covering the role of technology in the life sciences. He was the founding editor of Nature Genetics, the world's leading genetics journal, which he headed for its first five years. He has also written for the Times (London), Boston Globe, New England Journal of Medicine, and New Scientist, among others. His first book, Breakthrough (co-authored with Michael White) told the story of the race for the BRCA1 breast cancer gene. Davies holds an M.A. in biochemistry from the University of Oxford and a Ph.D in molecular genetics from the University of London. He held postdoctoral fellowships at MIT and Harvard Medical School before moving into science publishing as an editor with Nature magazine. He lives in Lexington, Massachusetts. --Ce texte fait référence à l'édition Relié .

Détails sur le produit

  • MP3 CD
  • Editeur : Tantor Media, Inc; Édition : Unabridged (21 septembre 2010)
  • Langue : Anglais
  • ISBN-10: 1400168503
  • ISBN-13: 978-1400168507
  • Dimensions du produit: 13,5 x 1,5 x 18,8 cm
  • Moyenne des commentaires client : 5.0 étoiles sur 5  Voir tous les commentaires (1 commentaire client)
  •  Souhaitez-vous compléter ou améliorer les informations sur ce produit ? Ou faire modifier les images?


En savoir plus sur l'auteur

Découvrez des livres, informez-vous sur les écrivains, lisez des blogs d'auteurs et bien plus encore.

Dans ce livre (En savoir plus)
Parcourir et rechercher une autre édition de ce livre.
Parcourir les pages échantillon
Couverture | Copyright | Table des matières | Extrait | Index | Quatrième de couverture
Rechercher dans ce livre:

Commentaires en ligne

4 étoiles
0
3 étoiles
0
2 étoiles
0
1 étoiles
0
5.0 étoiles sur 5
5.0 étoiles sur 5
Commentaires client les plus utiles
5.0 étoiles sur 5 Nice story about direct to costumer personal genomics 14 décembre 2012
Par TeoS
Format:Relié|Achat vérifié
Very well written; very interesting especially for those in the field of human genomic/next generation sequencing/personalized medicine via human genetics
Avez-vous trouvé ce commentaire utile ?
Commentaires client les plus utiles sur Amazon.com (beta)
Amazon.com: 3.7 étoiles sur 5  11 commentaires
18 internautes sur 20 ont trouvé ce commentaire utile 
3.0 étoiles sur 5 Great Premise But Not Many Insights 10 février 2011
Par Dr. Bojan Tunguz - Publié sur Amazon.com
Format:Relié|Achat vérifié
The dramatic ascension of genetics and our overall understanding of biology throughout the twentieth century had culminated with a dramatic and news-grabbing race to decode the entire human genome. This was a monumental achievement; especially since just a decade or two earlier even the most optimistic experts did not expect something like this to be accomplished for another hundred years or so. However, the remarkable improvements in the sequencing technologies and the computing tools, as well as the sudden realization by the entrepreneurs that genetics could be the new technological goldmine, all contributed to the rapid actualization of the dream that had been set in motion with the discovery of the DNA. The beginning of the twenty-first century was a time of great excitement and hope for the future of genomics and the ways it could impact medicine and lead to major improvements in our quality of life.

It has been more than a decade since those heady days of human genomics, and this seems like a good point in time to take a look and reflect on what has been accomplished since. However, it doesn't take a Ph.D. in biotechnology to conclude that in terms of therapeutic treatments, or even better understanding of many diseases, the actual impact of the decoding of the human genome has been minimal at best. It is quite possible that the main culprit for this state of affairs is the still prohibitive cost of mapping a single genome. This is an implicit premise of "The $1,000 Genome", and this book aims to explore many attempts to bring this cost down to the point where it becomes feasible to have your own genome decoded as a standard part of your medical screening. The book profiles many startups and semi-governmental efforts to improve the sequencing technology and make the personal genetic information more useful and applicable in the medical setting. However, the focus of the book is almost exclusively on the companies and the oversize egos who run them, and there is nary a word about the actual scientific/technical advances that have been developed over the course of the past ten years or so. It's like writing a book about the 1980s personal computer boom and not giving any insight into how those computers are made, what are their technical features, etc. Furthermore, there is very little critical assessment of the various companies and trends in personal genomics. This style of writing works fine for unbiased news articles, but is not the right kind of approach for an in-depth analysis of one of the most promising new technologies. Each chapter in the book is more or less unconnected to the other ones, and in this respect too this book reads like a collection of newspaper articles.

I really, really wanted to like this book. I am extremely fascinated with the new developments in biotechnology and personal medicine, and I have a strong appreciation for the industrial and entrepreneurial approaches in pushing the envelope of human knowledge. However, after reading "The $1,000 Genome" I failed to gain any overarching insight into where these developments may lead. This is a book with a lot of information on the genomics and biotech startups, but aside from the rapidly plummeting price tag of the sequencing of single human genome it offers very little to get excited about. This is unfortunate because I believe that we are on a verge of a radical change in the way that medical conditions are treated, and a good insightful book could have gone a long way in bringing the attention of the general public to this upcoming revolution.
6 internautes sur 6 ont trouvé ce commentaire utile 
4.0 étoiles sur 5 reporting the real genome revolution 4 janvier 2011
Par Michael Gross - Publié sur Amazon.com
Format:Relié
Back in 2000, when the draft sequence of "the" human genome was announced, hopes were high that a genetic understanding of common diseases would soon follow. This anticipated revolution in genomic medicine hasn't happened yet. However, a very different kind of revolution has happened, namely the development of fundamentally new and much more efficient methods to sequence huge amounts of DNA. As a consequence, the cost of sequencing a human genome has fallen faster than that of computer hardware. In order-of-magnitude terms, the first human genome (2000) cost around $ 1 billion, James Watson's (2007) $ 1 million, and this year many individual human genomes will be sequenced for not much more than $1000 per head.

This very real genome revolution has been underreported in the general media. Worse, it hasn't yet influenced the thinking of many medical professionals, even though it is bound to change the ways in which they will be able to prevent and treat disease. Kevin Davies, who has followed these developments closely as the editor of the magazine BioIT World and has interviewed many of the main protagonists over the years, now aims to popularise the new genome revolution in this very readable book.

Along with the progress in sequencing technology and personal genomes, Davies also covers the work of direct-to-consumer companies such as 23 and me, and also reports his own experience gained with these services. It emerges, however, that these companies are already at risk of becoming obsolete if they keep looking for simple answers from single base mutations (single nucleotide polymorphisms, or SNPs) although the large-scale view of the complexity of entire genomes is becoming more and more important.

This is a well-informed and very accessible account of the fast-moving developments that will change medical and pharmaceutical world very soon. Naturally, it will become dated very soon, so read it now.
20 internautes sur 26 ont trouvé ce commentaire utile 
3.0 étoiles sur 5 Disappointing - 12 octobre 2010
Par Loyd E. Eskildson - Publié sur Amazon.com
Format:Relié
I'm a biology illiterate excited by the prospects of genetic research and future genetic engineering. I was hoping that Davies' book would educate me in the basics, especially since his day job involves editing a periodical on the topic and he has a PhD in the subject. Unfortunately, Davies' book didn't do it. "The $1,000 Genome" focuses more on the key companies and leaders in the field, than explaining what's happening to neophytes. (Articles such as "The $100 Genome" in the 4/17/2008 "Technology Review" are more helpful.) As a result, the material jumps from one approach to another, and lacks a simple, structured approach. I also didn't appreciate Davies' wild numbers in some instances - eg. the U.S. spending $5 trillion on 4 million with Alzheimers.

Davies should also have devoted much more space to BGI (formerly Beijing Genomics Institute), which with its 126 new top-of-the-range sequencing machines added to an existing 31 will have supposedly more DNA-sequencing capacity than the entire U.S. Also important is what it is likely to accomplish, at least in the area of human intelligence, an area that it is focusing on. (2,000 Chinese children will have their genes sampled, and the results correlated with their test scores at school - the largest examination to date of the idea that differences between individuals' IQ scores are partly due to DNA differences.)

Nonetheless, it is impossible not to be impressed by the speed of improvement in the field - from taking 13 years and $2.7 billion to decade the first human genome , to 14 days and $1,500 by 2009. That's improvement by a factor of 10/year, far faster than even Moore's Law (doubling the number of transistors on a chip every 12-18 months). (The problem is, however, that given how Davies switches from sampling to partial DNA to entire DNA analysis, the reader is never certain whether these comparisons involve apples to apples.)

I also didn't appreciate the time Davies devoted to ethics and privacy concerns, vs. outcomes and methods.
1 internautes sur 1 ont trouvé ce commentaire utile 
2.0 étoiles sur 5 Profiles of Some People in the Sequencing Business 12 janvier 2014
Par Amazon Customer - Publié sur Amazon.com
Format:Format Kindle|Achat vérifié
The title of this review would be an alternative suggestion for the book title.

Don't read this looking to find more about sequencing technology or uses. The book has about the technical content of a USA today article.
Here's the full description of the rise of Curagen: "He invented a patented method for studying gene expression by looking up activity patterns in a database, which he dubbed "GeneCalling". Two sentences later the company "had raised some $600 million" and it's "estimated that his major investors each made $100 million". They made money by raising money? Or does the paragraph intend to say that Curagen was *sold* for $600M? Somebody paid $600M for a method of looking up patterns in a database? Really?

This is the book for you if you want descriptions of colorful characters and what they say about each other, reporting on parties and publicity events, anecdotes about genetic defects in the relatives of people involved in the companies, ethical issues in consumer sequencing, and other such human interest flotsam.

Not for you if you'd like to learn what the technology is and what can be done with it.
1 internautes sur 1 ont trouvé ce commentaire utile 
4.0 étoiles sur 5 Nice overview of the technology & the many commercial players 28 juillet 2012
Par Mark B Gerstein - Publié sur Amazon.com
Format:CD
This book gives an interesting overview of the field of next-generation sequencing and its implications for personal genomics. Kevin Davies provides a snapshot of the technology in the next-generation sequencing companies, in particular explaining how 454 capitalized on emulsion PCR, how Solexa contributed reversible terminator chemistry and cluster PCR, how Ion Torrent utilized the principles of a pH meter for sequencing, &c. He also gives a quick overview of all the personal genomics companies giving one a sense of their unique angle - i.e. deCODEme with its strong science capitalizing on the unique genetics of Iceland, Navigenics with its more medically oriented and paternalistic style and 23andme with its more social networking angle.

Davies also talks a little bit about how we should appreciate the results from personal genomics companies and how currently, except for the APOE gene, most of the results that we get would have very low odds ratios and effect sizes and are more of a curiosity -- but the whole enterprise has strong ethical implications.
Ces commentaires ont-ils été utiles ?   Dites-le-nous
Rechercher des commentaires
Rechercher uniquement parmi les commentaires portant sur ce produit

Discussions entre clients

Le forum concernant ce produit
Discussion Réponses Message le plus récent
Pas de discussions pour l'instant

Posez des questions, partagez votre opinion, gagnez en compréhension
Démarrer une nouvelle discussion
Thème:
Première publication:
Aller s'identifier
 

Rechercher parmi les discussions des clients
Rechercher dans toutes les discussions Amazon
   


Rechercher des articles similaires par rubrique


Commentaires

Souhaitez-vous compléter ou améliorer les informations sur ce produit ? Ou faire modifier les images?